grant
Mechanisms and means to improve HIV bnAb activity in vivo
NIHUS FederalResearch GrantFY2025AIDS VirusAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome VirusAffinityAnimal ModelAnimal Models and Related StudiesAntibodiesAntibody TherapyAntigenic DeterminantsAutomobile DrivingBenchmarkingBest Practice AnalysisBinding DeterminantsBlood PlasmaBody TissuesClinicalClinical Treatment MoabComplementComplement ProteinsDNA mutationDataDevelopmentDiseaseDisorderEngineeringEpitopesExhibitsFc domainGenetic ChangeGenetic defectGenetic mutationGlycoproteinsGoalsHIVHIV InfectionsHIV-1HIV-IHIV1HTLV-III InfectionsHTLV-III-LAV InfectionsHumanHuman Immunodeficiency Virus Type 1Human Immunodeficiency VirusesHuman T-Lymphotropic Virus Type III InfectionsHuman immunodeficiency virus 1In VitroIn vivo analysisIndividualInfectionInfection preventionInterventionIntervention StrategiesKnowledgeLAV-HTLV-IIILymphadenopathy-Associated VirusModelingModern ManMonitorMonoclonal AntibodiesMucosaMucosal TissueMucous MembraneMutationOutcomePlasmaPlasma SerumPopulationPrEPPredispositionPrevent infectionPreventionProphylactic treatmentProphylaxisReticuloendothelial System, Serum, PlasmaSHIVSusceptibilitySystemic infectionTestingTissuesTranslational ResearchTranslational ScienceTransmissionTreatment EfficacyVaccine DesignViralViral ActivityViral AntibodiesViral BurdenViral FunctionViral LoadViral Load resultViral PhysiologyViral reservoirViremiaVirusVirus reservoirVirus-HIVWorkanti-viral antibodyantibody based therapiesantibody engineeringantibody treatmentantibody-based therapeuticsantibody-based treatmentbenchmarkclinical applicabilityclinical applicationclinical efficacycomplementationdesigndesigningdevelop a vaccinedevelop vaccinesdevelopment of a vaccinedevelopmentaldrivingefficacy clinical trialgenome mutationimprovedimproved outcomein vivoin vivo evaluationin vivo testinginfection riskinnovateinnovationinnovativeinsightintervention efficacymAbsmodel of animalmonoclonal Absneutralizing antibodynext generationnon-human primatenonhuman primatepathogenpre-clinical researchpre-exposure prophylaxispreclinical researchpreventpreventingprevention efficacy trialsimian HIVsimian human immunodeficiency virussmall molecular inhibitorsmall molecule inhibitorsynergismtherapeutic efficacytherapy efficacytranslation researchtranslational investigationtransmission processvaccine developmentviraemiaviral sepsisvirusemia
Description preview
ABSTRACT
A number of anti-HIV-1 broadly neutralizing antibodies (bNAbs) targeting highly conserved and vulnerable
epitope regions of the envelope glycoprotein (Env) are being investigated for a range of clinical applications
based on their ability to robustly prevent infection in a variety of animal models. Successful monoclonal
antibody (mAb)…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click